Compumedics !!!!!!

--------------------------------------------------------------------------------

29/07/2002 10:07:42
Letter of Intent signed with Drager Medical

COMPUMEDICS LIMITED 2002-07-29 ASX-SIGNAL-G

HOMEX - Melbourne

+++++++++++++++++++++++++
Compumedics Ltd (ASX:CMP) headquartered in Melbourne, Australia, and
Pre & Post Hospital Care, a division of Drager Medical AG & Co KGaA,
headquartered in Luebeck, Germany, have signed a letter of intent for
the supply and development of sleep diagnostic technology.

Compumedics expects to realize an additional sales revenue of
approximately AUD$ one million (approx E0.55 million) in the initial
12-month contract period. Drager Medical will have exclusive sales
and marketing rights in Germany for Compumedics' Somte(TM)
cardio-respiratory monitoring units and non-exclusive rights in
France and Benelux. Both parties have also confirmed their intention
to cooperate on a broader technological and strategic basis.

The Somte(TM) system is a first of its kind - a lightweight medical
recorder that combines features of diagnostic sleep systems and
cardiac holter recorders. The very small (200 gram) device can be
used by a patient at home to provide information for early detection
of cardiac dysfunction. Somte(TM) was released to the European market
only three months ago after receiving the required European Union CE
regulatory approval.

Compumedics Executive Chairman, David Burton said, "To have a partner
of the international standing of Drager Medical is a significant
boost for Compumedics. The relationship will not only provide ready
access to an important part of the European sleep diagnostics market,
but also give us a technology partner without peer to work with on
the commercialization of new products."

The link is important for Compumedics' revamped international
distribution strategy. "We are now able to work with world class
companies such as Drager Medical to take Compumedics' sleep
technology to European customers," David Burton added.

Dr M Thijs A Teeling, General Manager, Pre & Post Hospital Care,
Drager Medical said, "The portable Somte(TM) diagnostic system is
ideally suited for the home health care sector, which has become a
major area of focus for our business. We are a leader in
state-of-the-art medical technologies, so adding the supply of sleep
diagnostic technology to our current product portfolio was a natural
fit. Finally, we look forward to working with Compumedics to develop
other products for the European markets."

The diagnosis and treatment of sleep disorders is a rapidly growing
field of medicine worldwide. In the United States alone, there are
already 2400 specialist sleep treatment centres, with the market
growing at over 10% per annum.

PRESS CONTACT:

Compumedics:
David Burton
EXECUTIVE CHAIRMAN, CEO
Phone: +61 3 8413 7300
Fax: +61 3 8413 7399
[email protected]

Drager Medical:
Bjoern Woelke
PR MANAGER
CORPORATE COMMUNICATIONS
Phone: +49 451 882-2009
Fax: +49 451 882-3197
[email protected]


ABOUT COMPUMEDICS

For more information, please visit: www.compumedics.com.au

ABOUT DRAGER MEDICAL

Drager Medical AG & Co KGaA is one of the world's leading
manufacturers of medical equipment. As the largest division of
Dragerwerk AG, Drager Medical offers integrated systems and services
throughout the entire patient care process in clinical acute care and
the home care sector. Drager Medical employs approximately 4,800
people worldwide and is represented in over 100 countries. Over the
past six years, the company continually boosted its sales by more
than 10% a year, reaching a total of 805 million Euro in fiscal 2001.
In the same period, the company quadrupled its EBIT from 9.1 million
Euro to 39.0 million Euro. The innovative concepts of Drager Medical
are the result of close dialogue with customers, years of experience
in the market, and significant investment in R&D. The company's goal
is to improve the quality of patient care while supporting cost
reduction in the health care sector.
For more information, please visit: www.draeger.com.


Rising from an oversold base of .145

Good Trading
Ytrade